Form 4: Supernus Director Exercises Stock Options

Supernus Pharmaceuticals Director Charles W. Newhall III exercised options to acquire 15,000 shares of common stock at $12.98 per share.

Summary

• Charles W. Newhall III, a Director of Supernus Pharmaceuticals, Inc. (SUPN), acquired 15,000 shares of common stock.
• The transaction occurred on November 21, 2025, through the exercise of a Director Stock Option.
• The exercise price for the shares was $12.98 per share.
• Following this transaction, Mr. Newhall beneficially owns 119,644 shares of Supernus Pharmaceuticals common stock directly.
• The exercised options were originally exercisable from March 1, 2017, and had an expiration date of March 1, 2026.

Sentiment

Score: 7

Explanation: The exercise of stock options by a director to increase their direct ownership is generally viewed as a positive signal, indicating confidence in the company's valuation and future performance.

Positives

• A company director increased their direct ownership stake by acquiring 15,000 shares, signaling confidence in the company's future prospects.
• The exercise of stock options at a set price indicates a planned transaction, often reflecting long-term commitment.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, such as option exercises, are common in the pharmaceutical industry as a component of executive and director compensation. An increase in insider ownership can be viewed by the market as a positive signal, indicating management's belief in the company's future prospects, especially in a sector often characterized by long development cycles and regulatory hurdles.

Related Party Transactions

• The transaction involves a company director, Charles W. Newhall III, acquiring shares from the issuer, Supernus Pharmaceuticals, Inc., through the exercise of stock options, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this insider buying as a positive indicator of management confidence, potentially influencing investor sentiment and stock valuation.
• Employees and other stakeholders might interpret the director's increased stake as a sign of stability and belief in the company's long-term strategy.

Key Dates

Recommendation

The acquisition of 15,000 shares by a director through option exercise, increasing their direct beneficial ownership, signals strong insider confidence in Supernus Pharmaceuticals' future. This type of insider buying often precedes positive company performance and can be a compelling signal for investors to consider a 'buy' position, assuming other fundamental analyses align.

Keywords

Supernus Pharmaceuticals, SUPN, Insider Transaction, Form 4, Stock Option Exercise, Director Stock, Beneficial Ownership, Pharmaceuticals